Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Cancer‐related anemia (CRA) is due to multiple etiologies, including chemotherapy‐induced
myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to …

Background First-line (1L) immunotherapy (IO) has improved outcomes in patients with
advanced non-small cell lung cancer (NSCLC) in clinical trials and is now routinely used alone …

Introduction Until recently, systemic chemotherapy was the only option for treating bladder
cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-…

Purpose: To assess the association of tumor mutational burden (TMB) with clinical outcomes,
other biomarkers and patient/disease characteristics in patients receiving therapy for lung …

The extent to which immune cell phenotypes in the peripheral blood reflect within-tumor
immune activity prior to and early in cancer therapy is unclear. To address this question, we …

Background Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are
a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is …

Pharmacogenetic (PGx) literature has shown beneficial outcomes in safety, efficacy and
cost when evidence-based gene-drug decision making is incorporated into clinical practice. …

Multiple myeloma is a malignancy involving plasma cell proliferation within the bone marrow.
Survival of patients diagnosed with myeloma has significantly improved in the last decade, …

Two decades of molecular research have revealed the presence of transporters and receptors
expressed in the brain vascular endothelium that provide potential novel targets for the …